ELI LILLY AND COMPANY Other Comprehensive Income (Loss), Tax
ELI LILLY AND COMPANY (LLY) reported Other Comprehensive Income (Loss), Tax of -$306.80 million for the 3-month period ending 2025-06-30, per its 10-Q filed 2025-08-07.
Financial Statements › Expense Statement › Income Tax
us-gaap:OtherComprehensiveIncomeLossTax · last filed 2025-08-07
- ELI LILLY AND COMPANY other comprehensive income (loss), tax for the quarter ending 2025-06-30 was -$306.80M, a 1533.64% decline year-over-year.
- ELI LILLY AND COMPANY other comprehensive income (loss), tax for the quarter ending 2025-03-31 was -$115.80M, a 278.70% decline year-over-year.
- ELI LILLY AND COMPANY other comprehensive income (loss), tax for the quarter ending 2024-12-31 was $330.80M.
- ELI LILLY AND COMPANY other comprehensive income (loss), tax for the quarter ending 2024-09-30 was -$122.30M, a 206.07% decline year-over-year.
- ELI LILLY AND COMPANY other comprehensive income (loss), tax for fiscal 2024 was $294.70M.
- ELI LILLY AND COMPANY other comprehensive income (loss), tax for fiscal 2023 was -$196.30M, a 178.52% decline from fiscal 2022.
- ELI LILLY AND COMPANY other comprehensive income (loss), tax for fiscal 2022 was $250.00M, a 64.04% decline from fiscal 2021.
- ELI LILLY AND COMPANY other comprehensive income (loss), tax for fiscal 2021 was $695.30M.
| Period end | Other Comprehensive Income (Loss), Tax 3 month | Other Comprehensive Income (Loss), Tax 3 month as first filed | Other Comprehensive Income (Loss), Tax 6 month | Other Comprehensive Income (Loss), Tax 6 month as first filed | Other Comprehensive Income (Loss), Tax 9 month | Other Comprehensive Income (Loss), Tax 12 month |
|---|---|---|---|---|---|---|
| 2025-06-30 | -$306.80M 10-Q · filed 2025-08-07 | -$422.60M 10-Q · filed 2025-08-07 | -$91.80M derived: sum of 3 quarters · filed 2025-08-07 | -$214.10M derived: sum of 4 quarters · filed 2025-08-07 | ||
| 2025-03-31 | -$115.80M 10-Q · filed 2025-05-01 | $215.00M derived: sum of 2 quarters · filed 2025-05-01 | $92.70M derived: sum of 3 quarters · filed 2025-05-01 | $114.10M derived: sum of 4 quarters · filed 2025-08-07 | ||
| 2024-12-31 | $330.80M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | $208.50M derived: sum of 2 quarters · filed 2025-02-19 | $229.90M derived: sum of 3 quarters · filed 2025-08-07 | $294.70M 10-K · filed 2025-02-19 | ||
| 2024-09-30 | -$122.30M 10-Q · filed 2024-10-30 | -$100.90M derived: sum of 2 quarters · filed 2025-08-07 | -$36.10M 10-Q · filed 2024-10-30 | -$331.50M derived: sum of 4 quarters · filed 2025-08-07 | ||
| 2024-06-30 | $21.40M 10-Q · filed 2025-08-07 | $86.20M 10-Q · filed 2025-08-07 | -$209.20M derived: sum of 3 quarters · filed 2025-08-07 | -$93.90M derived: sum of 4 quarters · filed 2025-08-07 | ||
| 2024-03-31 | $64.80M 10-Q · filed 2025-05-01 | -$230.60M derived: sum of 2 quarters · filed 2025-05-01 | -$115.30M derived: sum of 3 quarters · filed 2025-05-01 | -$95.50M derived: sum of 4 quarters · filed 2025-05-01 | ||
| 2023-12-31 | -$295.40M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | -$180.10M derived: sum of 2 quarters · filed 2025-02-19 | -$160.30M derived: sum of 3 quarters · filed 2025-02-19 | -$196.30M 10-K · filed 2025-02-19 | ||
| 2023-09-30 | $115.30M 10-Q · filed 2024-10-30 | $135.10M derived: sum of 2 quarters · filed 2024-10-30 | $99.10M 10-Q · filed 2024-10-30 | -$26.00M derived: sum of 4 quarters · filed 2025-02-19 | ||
| 2023-06-30 | $19.80M 10-Q · filed 2024-08-08 | -$16.20M 10-Q · filed 2024-08-08 | -$141.30M derived: sum of 3 quarters · filed 2025-02-19 | $27.90M derived: sum of 4 quarters · filed 2025-02-19 | ||
| 2023-03-31 | -$36.00M 10-Q · filed 2024-04-30 | -$161.10M derived: sum of 2 quarters · filed 2025-02-19 | $8.10M derived: sum of 3 quarters · filed 2025-02-19 | $148.70M derived: sum of 4 quarters · filed 2025-02-19 | ||
| 2022-12-31 | -$125.10M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | $44.10M derived: sum of 2 quarters · filed 2025-02-19 | $184.70M derived: sum of 3 quarters · filed 2025-02-19 | $250.00M 10-K · filed 2025-02-19 | ||
| 2022-09-30 | $169.20M 10-Q · filed 2023-11-02 | $309.80M derived: sum of 2 quarters · filed 2023-11-02 | $375.10M 10-Q · filed 2023-11-02 | $864.30M derived: sum of 4 quarters · filed 2024-02-21 | ||
| 2022-06-30 | $140.60M 10-Q · filed 2023-08-08 | $205.90M 10-Q · filed 2023-08-08 | $695.10M derived: sum of 3 quarters · filed 2024-02-21 | $766.90M derived: sum of 4 quarters · filed 2024-02-21 | ||
| 2022-03-31 | $65.30M 10-Q · filed 2023-04-27 | $554.50M derived: sum of 2 quarters · filed 2024-02-21 | $626.30M derived: sum of 3 quarters · filed 2024-02-21 | $634.20M derived: sum of 4 quarters · filed 2024-02-21 | ||
| 2021-12-31 | $489.20M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | $561.00M derived: sum of 2 quarters · filed 2024-02-21 | $568.90M derived: sum of 3 quarters · filed 2024-02-21 | $695.30M 10-K · filed 2024-02-21 | ||
| 2021-09-30 | $71.80M 10-Q · filed 2022-11-01 | $79.70M derived: sum of 2 quarters · filed 2022-11-01 | $206.10M 10-Q · filed 2022-11-01 | $107.30M derived: sum of 4 quarters · filed 2023-02-22 | ||
| 2021-06-30 | $7.90M 10-Q · filed 2022-08-04 | $134.30M 10-Q · filed 2022-08-04 | $35.50M derived: sum of 3 quarters · filed 2023-02-22 | $800.00K derived: sum of 4 quarters · filed 2023-02-22 | ||
| 2021-03-31 | $170.30M 10-Q · filed 2022-04-29 | $27.60M derived: sum of 2 quarters · filed 2023-02-22 | -$7.10M derived: sum of 3 quarters · filed 2023-02-22 | -$3.50M derived: sum of 4 quarters · filed 2023-02-22 | ||
| 2020-12-31 | -$142.70M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | -$177.40M derived: sum of 2 quarters · filed 2023-02-22 | -$173.80M derived: sum of 3 quarters · filed 2023-02-22 | -$200.90M 10-K · filed 2023-02-22 | ||
| 2020-09-30 | -$34.70M 10-Q · filed 2021-10-27 | -$31.10M derived: sum of 2 quarters · filed 2021-10-27 | -$58.20M 10-Q · filed 2021-10-27 | -$264.60M derived: sum of 4 quarters · filed 2022-02-23 | ||
| 2020-06-30 | $3.60M 10-Q · filed 2021-08-03 | -$23.50M 10-Q · filed 2021-08-03 | -$229.90M derived: sum of 3 quarters · filed 2022-02-23 | -$209.60M derived: sum of 4 quarters · filed 2022-02-23 | ||
| 2020-03-31 | -$27.20M 10-Q · filed 2021-04-30 | -$233.50M derived: sum of 2 quarters · filed 2022-02-23 | -$213.20M derived: sum of 3 quarters · filed 2022-02-23 | -$205.70M derived: sum of 4 quarters · filed 2022-02-23 | ||
| 2019-12-31 | -$206.30M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-23 | -$186.00M derived: sum of 2 quarters · filed 2022-02-23 | -$178.50M derived: sum of 3 quarters · filed 2022-02-23 | -$151.00M 10-K · filed 2022-02-23 | ||
| 2019-09-30 | $20.30M 10-Q · filed 2020-10-28 | $27.80M derived: sum of 2 quarters · filed 2020-10-28 | $55.30M 10-Q · filed 2020-10-28 | -$117.10M derived: sum of 4 quarters · filed 2021-02-17 | ||
| 2019-06-30 | $7.50M 10-Q · filed 2020-07-31 | $35.00M 10-Q · filed 2020-07-31 | -$137.40M derived: sum of 3 quarters · filed 2021-02-17 | $9.00M derived: sum of 4 quarters · filed 2021-02-17 | ||
| 2019-03-31 | $27.50M 10-Q · filed 2020-05-01 | -$144.90M derived: sum of 2 quarters · filed 2021-02-17 | $1.50M derived: sum of 3 quarters · filed 2021-02-17 | $93.00M derived: sum of 4 quarters · filed 2021-02-17 | ||
| 2018-12-31 | -$172.40M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-17 | -$26.00M derived: sum of 2 quarters · filed 2021-02-17 | $65.50M derived: sum of 3 quarters · filed 2021-02-17 | $30.30M 10-K · filed 2021-02-17 | ||
| 2018-09-30 | $146.40M 10-Q · filed 2019-10-25 | $237.90M derived: sum of 2 quarters · filed 2019-10-25 | $202.70M 10-Q · filed 2019-10-25 | -$57.60M derived: sum of 4 quarters · filed 2020-02-19 | ||
| 2018-06-30 | $91.50M 10-Q · filed 2019-08-02 | $56.30M 10-Q · filed 2019-08-02 | -$204.00M derived: sum of 3 quarters · filed 2020-02-19 | -$223.00M derived: sum of 4 quarters · filed 2020-02-19 | ||
| 2018-03-31 | -$35.50M 10-Q · filed 2019-05-02 | -$35.20M 10-Q · filed 2018-04-27 | -$295.50M derived: sum of 2 quarters · filed 2020-02-19 | -$314.50M derived: sum of 3 quarters · filed 2020-02-19 | -$400.20M derived: sum of 4 quarters · filed 2020-02-19 | |
| 2017-12-31 | -$260.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-19 | -$279.00M derived: sum of 2 quarters · filed 2020-02-19 | -$364.70M derived: sum of 3 quarters · filed 2020-02-19 | -$402.70M 10-K · filed 2020-02-19 | ||
| 2017-09-30 | -$19.00M 10-Q · filed 2018-11-06 | -$104.70M derived: sum of 2 quarters · filed 2018-11-06 | -$142.70M 10-Q · filed 2018-11-06 | -$216.20M derived: sum of 4 quarters · filed 2019-10-24 | ||
| 2017-06-30 | -$85.70M 10-Q · filed 2018-07-25 | -$123.70M 10-Q · filed 2018-07-25 | -$197.20M derived: sum of 3 quarters · filed 2019-10-24 | -$174.70M derived: sum of 4 quarters · filed 2019-10-24 | ||
| 2017-03-31 | -$38.00M 10-Q · filed 2018-04-27 | -$111.50M derived: sum of 2 quarters · filed 2019-10-24 | -$89.00M derived: sum of 3 quarters · filed 2019-10-24 | -$30.90M derived: sum of 4 quarters · filed 2019-10-24 | ||
| 2016-12-31 | -$73.50M derived: 8-K 12 month − 10-Q 9 month · filed 2019-10-24 | -$51.00M derived: sum of 2 quarters · filed 2019-10-24 | $7.10M derived: sum of 3 quarters · filed 2019-10-24 | $10.60M 8-K · filed 2019-10-24 | ||
| 2016-09-30 | $22.50M 10-Q · filed 2017-10-27 | $80.60M derived: sum of 2 quarters · filed 2017-10-27 | $84.10M 10-Q · filed 2017-10-27 | $218.10M derived: sum of 4 quarters · filed 2018-02-20 | ||
| 2016-06-30 | $58.10M 10-Q · filed 2017-07-28 | $61.60M 10-Q · filed 2017-07-28 | $195.60M derived: sum of 3 quarters · filed 2018-02-20 | $228.70M derived: sum of 4 quarters · filed 2018-02-20 | ||
| 2016-03-31 | $3.50M 10-Q · filed 2017-05-01 | $137.50M derived: sum of 2 quarters · filed 2018-02-20 | $170.60M derived: sum of 3 quarters · filed 2018-02-20 | $161.80M derived: sum of 4 quarters · filed 2018-02-20 | ||
| 2015-12-31 | $134.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-20 | $167.10M derived: sum of 2 quarters · filed 2018-02-20 | $158.30M derived: sum of 3 quarters · filed 2018-02-20 | $121.90M 10-K · filed 2018-02-20 | ||
| 2015-09-30 | $33.10M 10-Q · filed 2016-10-28 | $24.30M derived: sum of 2 quarters · filed 2016-10-28 | -$12.10M 10-Q · filed 2016-10-28 | -$373.90M derived: sum of 4 quarters · filed 2017-02-21 | ||
| 2015-06-30 | -$8.80M 10-Q · filed 2016-07-28 | $8.80M 10-Q · filed 2015-07-30 | $45.20M 10-Q · filed 2016-07-28 | -$45.20M 10-Q · filed 2015-07-30 | -$407.00M derived: sum of 3 quarters · filed 2017-02-21 | -$404.30M derived: sum of 4 quarters · filed 2017-02-21 |
| 2015-03-31 | $54.00M 10-Q · filed 2016-04-29 | -$398.20M derived: sum of 2 quarters · filed 2017-02-21 | -$395.50M derived: sum of 3 quarters · filed 2017-02-21 | -$397.90M derived: sum of 4 quarters · filed 2017-02-21 | ||
| 2014-12-31 | -$452.20M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-21 | -$449.50M derived: sum of 2 quarters · filed 2017-02-21 | -$451.90M derived: sum of 3 quarters · filed 2017-02-21 | -$476.60M 10-K · filed 2017-02-21 | ||
| 2014-09-30 | $2.70M 10-Q · filed 2015-10-30 | $300.00K derived: sum of 2 quarters · filed 2015-10-30 | -$24.40M 10-Q · filed 2015-10-30 | |||
| 2014-06-30 | -$2.40M 10-Q · filed 2015-07-30 | -$27.10M 10-Q · filed 2015-07-30 | ||||
| 2013-12-31 | $914.50M 10-K · filed 2016-02-19 | |||||
| 2012-12-31 | $68.00M 10-K · filed 2015-02-19 | |||||
| 2011-12-31 | -$430.20M 10-K · filed 2014-02-19 | |||||
| 2010-12-31 | $76.20M 10-K · filed 2013-02-21 | |||||
| 2009-12-31 | $27.70M 10-K · filed 2012-02-24 | |||||
| 2008-12-31 | -$1.07B 10-K · filed 2011-02-22 | |||||
| 2007-12-31 | $287.00M 10-K · filed 2010-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |